Biomerix Receives CE Mark Approval For ASSURE Soft Tissue Repair Mesh

Incorporating the Biomerix Biomaterial, an innovative synthetic tissue scaffold

FREMONT, Calif., Jan. 5, 2012 — /PRNewswire/ — Biomerix Corporation announced today that it has received CE Mark approval  for its ASSURE soft tissue repair mesh, a novel composite mesh intended for the reconstruction of hernias and soft tissue deficiencies and for the temporary bridging of fascial defects.  This approval allows Biomerix to distribute ASSURE throughout Europe and support certification in many other parts of the world that recognize the CE Mark for commercial distribution purposes.  ASSURE is constructed of three distinct layers, each layer providing an important function in the repair of a hernia or soft tissue deficiency.  The first layer consists of the Biomerix Biomaterial, a proprietary, biointegrative synthetic polyurethane tissue scaffold designed to play a role similar to that of the body’s extracellular matrix, a biological structure that supports tissue repair and regeneration.  The second layer is a knitted polypropylene monofilament mesh which provides mechanical support for a strong, durable and flexible repair.  The third layer consists of a resorbable lactide caprolactone copolymer film designed to minimize tissue attachment to the device in case of direct contact with the viscera.”ASSURE’s distinctive multi-layered design reflects extensive market research to address patient comfort and surgeon ease-of-use in open and laparoscopic (minimally invasive) hernia repair procedures.  The device incorporates the unique properties of a biologic tissue scaffold to support tissue regeneration with the best properties of a synthetic biomaterial in terms of its strength and durability,” said Kenneth G. Hayes, President and CEO of Biomerix Corporation.  ”ASSURE is already available in the United States after receiving a 510(k) clearance from the U.S. Food and Drug Administration (FDA) in May 2010.  We are thrilled with the initial US experience to date and believe that ASSURE will provide substantial clinical benefits to patients.”

About Biomerix Corporation

Biomerix Corporation is recognized as a leader in the development and manufacturing of innovative non-absorbable and bioresorbable three-dimensional, open-cell, resilient elastomeric polyurethane biomaterials.  The Company’s expertise includes the development, co-development and supply of new proprietary materials, products and components to customers in the medical, industrial and consumer industry markets.For more information please visit www.biomerix.com or call 888.308.3620.

Just Add Cells: Preassembled, Single-Use Disposable Scaffold + Plasticware Combination

Greenville, SC and Somerset, NJ – December 2, 2011

Biomerix Corporation and KIYATEC announced today a relationship through which high value, high impact microphysiological systems research takes a major leap forward with the launch of 3DKUBE™ – Biomerix 3D Scaffold™ Preloads.  By combining 3D scaffolds and perfusion 3D cell culture plasticware in a preassembled, single-use disposable format, the companies have achieved an industry first.  The new product will allow 3D cell culture researchers to “just add cells” via perfusion seeding into each Biomerix 3D Scaffold™ housed inside KIYATEC’s 3DKUBE™ 3D Cell Culture Plasticware.  Researchers can now economically and conveniently access the huge benefits of actively perfusing their 3D cell-scaffold constructs without having to make or manipulate scaffolds.

The preloaded product incorporates the Biomerix 3D Scaffold™, a non-resorbable polycarbonate polyurethane-urea scaffold matrix structurally designed to mimic the nature and function of the extracellular matrix (ECM).  Each scaffold has an interconnected 3D network of cells and pores with 90-95% accessible void content, and provides an in vitro cell culture environment that promotes cellular organization, cell-matrix and cell-cell interactions, cellular proliferation and ECM synthesis.   To create the new product, the Biomerix 3D Scaffold™ disks are preloaded into a KIYATEC 3DKUBE™ in an “Independent Chambers” configuration and benefit from its leading combination of universality, features and cost-effectiveness.

KIYATEC CEO Matt Gevaert, PhD will take the stage to provide more details in Denver, Colorado on Tuesday, December 6th.  He will discuss this and other product innovations during the company’s Exhibitor Showcase workshop at the 2011 Annual Meeting of the American Society for Cell Biology.   KIYATEC’s Exhibitor Showcase is sponsored by Sigma Life Sciences, a leading life science and high technology company with $2.3 billion in sales of chemicals and laboratory equipment in 2010.  Sigma distributes KIYATEC’s 3D cell culture products.  The new product will also be featured at KIYATEC’s exhibit booth over the course of the three-day meeting.

About KIYATEC
KIYATEC Inc. is a life sciences company commercializing advanced three-dimensional (3D) cell culture plasticware and 3D cell-based assays.  3DKUBE™ 3D Cell Culture Plasticware creates a universal system offering a standardized approach to 3D cell culture.  It is the only 3D cell culture platform that incorporates perfusion flow, accommodates all scaffold materials, allows in situ imaging, models biological complexity using multiple co-segregated culture chambers, and features the cost-effective benefits of being a single-use disposable. KIYATEC’s 3D cell-based assays leverage the advantages of the 3DKUBE™ to create high value, high impact cell culture that creates better in vitro prediction of complex biochemical responses in humans, with a focus on evaluation of drug toxicity and efficacy prior to use in human clinical trials.
Discover. Develop. Diagnose.™  KIYATEC 3D Cell Culture Delivers.  For more information about KIYATEC, visit www.kiyatec.com.

About Biomerix Corporation
Biomerix Corporation is recognized as a leader in the development and manufacturing of innovative non-absorbable and bioresorbable three-dimensional, open-cell, resilient elastomeric polyurethane biomaterials.  The Company’s expertise includes the development, co-development and supply of new proprietary materials, products and components to customers in the medical, industrial and consumer industries.
For more information please visit www.biomerix.com or call 888.308.3620.

Biomerix Corporation and Gel Company Announce Strategic Distribution Agreement

The Biomerix 3D Scaffold to be Marketed to the Life Science Community

FREMONT, Calif., July 19, 2011 / PRNewswire/ — Biomerix Corporation and Gel Company today announced a strategic distribution agreement for the Biomerix 3D Scaffold, a novel three-dimensional tissue scaffold. Under the agreement, Gel Company will market and distribute the Biomerix 3D Scaffold to researchers in the life science community across the United States.

The Biomerix 3D Scaffold consists of a non-degradable, open-cell polycarbonate polyurethane, designed to mimic the nature and function of the extracellular matrix (ECM). Its unique three-dimensional microarchitecture embodies a network of interconnecting cells and pores constructed to support tissue ingrowth, allowing researchers to study cells in an environment that simulates the conditions of cells in the body.  The unique chemistry and macroporous structure of the Biomerix 3D Scaffold supports the growth of myriad cell types and delivers more predictive results compared to standard 2D cell culture systems.  The proprietary Biomerix Biomaterial, used to manufacture the Biomerix 3D Scaffold has been demonstrated to support optimal cell proliferation and superior cell viability in both in-vitro and in-vivo studies and has received seven US and international regulatory clearances for a variety of indications.

“We have already experienced interest in the Biomerix 3D Scaffold, and we are delighted to add this innovative technology to our portfolio of products”, said Greg Richardson, President of the Gel Company. “The Biomerix 3D Scaffold is an excellent fit with our expertise in the life science research community.”

“Biomerix is very pleased to have the Gel Company become one of our distribution partners.  Their reputation as a quality supplier, as well as their commitment to customer service, was appealing to Biomerix”, stated Kenneth Hayes, President and Chief Executive Officer of Biomerix Corporation.   “We look forward to a long and prosperous partnership with the Gel Company.”

About Biomerix Corporation

Biomerix Corporation is recognized as a leader in the development and manufacturing of innovative non-absorbable and bioresorbable three-dimensional, open-cell, resilient elastomeric polyurethane biomaterials.  The Company’s expertise includes the development, co-development and supply of new proprietary materials, products and components to customers in the medical, industrial and consumer industry markets.

For more information please visit www.biomerix.com or call 888.308.3620.

About Gel Company

Gel Company develops, manufactures and supplies innovative tools for Proteomics, Genomics, Cell Biology, Liquid Handling and Microarray to scientists around the world.  We provide products with superior performance that are simple, safe to use and that are environmentally friendly.  The company has a team of experienced scientists dedicated to developing new technologies and products as well as providing the highest level of customer support.

For more information please visit www.gelcompany.com.

Biomerix Corporation Reaches European Distribution Agreement with Cellon S.A.

The Biomerix 3D Scaffold to be Marketed for Use in Regenerative Medicine Research

FREMONT, Calif., May 18, 2011 / PRNewswire/ — Biomerix Corporation and Cellon today announced a strategic distribution agreement for the Biomerix 3D Scaffold, a novel three-dimensional tissue scaffold. Under the agreement, Cellon will market and distribute the Biomerix 3D Scaffold to research institutions across Europe.

Comprised of a non-degradable, three-dimensional, open-cell polycarbonate polyurethane, the Biomerix 3D Scaffold is designed to mimic the nature and function of the extracellular matrix (ECM). Its novel macroporous microarchitecture consists of a network of interconnecting cells and pores, creating an environment highly conducive to applications in regenerative medicine, drug discovery, and stem cell research.  The unique chemistry and microarchitecture of the Biomerix 3D Scaffold has been demonstrated to support optimal cell proliferation and superior cell viability in both in-vitro and in-vivo studies involving diverse cell types, including hematopoetic stem cells, mesenchymal stem cells, induced pluripotent stem cells, human adipose stem cells, human osteoblasts, fibroblasts, and fibrochondrocytes.

“Biomerix is delighted to form this new strategic partnership with Cellon, further strengthening each company’s European presence in the field of regenerative medicine, tissue engineering, and drug discovery,> development and delivery.  The proprietary Biomerix Biomaterial used to manufacture the Biomerix 3D Scaffold has received seven US and international regulatory clearances for different indications in soft tissue repair, orthopedics, and vascular embolization,” said Kenneth Hayes, President and Chief Executive Officer of Biomerix Corporation.

About Biomerix Corporation

Biomerix Corporation is recognized as a leader in the development and manufacturing of innovative non-absorbable and bioresorbable three-dimensional, open-cell, resilient elastomeric polyurethane biomaterials.  The Company’s expertise includes the development, co-development and supply of new proprietary materials, products and components to customers in the medical, industrial and consumer industry markets.

For more information please visit www.biomerix.com or call 888.308.3620.

About Cellon S.A.

CELLON is a rapidly growing company, established in 1987 to provide products and services to the vaccine production and bioprocessing industries. Areas of expertise include mammalian cell culture processes and the storage & transport of sterile liquids. Our success to-date has been built upon an understanding of the requirements of this demanding business sector – which has led to the formation of many collaborative relationships with our customers. Such partnerships have enabled us to develop a range of products to meet specific industry needs – in unique, often revolutionary, ways.

For more information please visit www.cellon.lu

Biomerix Awarded Two Device Licenses by Health Canada

REVIVE and ASSURE Hernia Repair Meshes to be Marketed in Canada by Medline Industries

FREMONT, Calif., April 19, 2011 — Biomerix Corporation announced today it has received two Class III Medical Device Licenses by Health Canada for its REVIVE and ASSURE Hernia Repair Meshes.

REVIVE and ASSURE surgical meshes feature the Biomerix Biomaterial, a proprietary, biointegrative, synthetic tissue scaffold. The Biomerix Biomaterial is designed to play a role similar to the body’s extracellular matrix, a biological structure that supports tissue repair and regeneration.  The three-dimensional, open-cell, and interconnected structure allows cells to migrate and proliferate to create new tissue. These meshes combine the strength of a synthetic material with the properties of a biologic, each offering its own set of distinctive benefits.

REVIVE is constructed with the Biomerix Biomaterial on both sides to maximize tissue ingrowth, a critical element in the repair of inguinal hernias. ASSURE is created for the repair of ventral hernias, with one side composed of the Biomerix Biomaterial to promote  tissue ingrowth and the opposite side consisting of a resorbable protective film designed to minimize tissue attachment to the device in case of direct contact with the viscera.

“These regulatory approvals represent another step forward as Biomerix broadens its global reach with REVIVE and ASSURE. Both products will be distributed in Canada by Medline Industries pursuant to our exclusive distribution agreement,” stated Kenneth G. Hayes, President and CEO of Biomerix Corporation.

About Biomerix

Biomerix Corporation develops and manufactures novel and proprietary materials to meet the needs of the medical, industrial, and consumer markets. Founded in 2001, Biomerix began developing a new class of polymeric material designed to support the tissue healing process. By 2004, the Company achieved a significant breakthrough and created the proprietary Biomerix Biomaterial™, a revolutionary biointegrative synthetic tissue scaffold. The Biomerix Biomaterial is a non-resorbable, cross linked, reticulated, polycarbonate polyurethane-urea consisting of an open-cell, three-dimensional, interconnected macroporous structure. This unique scaffold translates into an ability to support predictable, organized fibrovascular tissue ingrowth. The Biomerix Biomaterial is designed to play a role similar to the body’s extracellular matrix (ECM), through the main monopril phases of inflammation, proliferation, and remodeling.

For more information please call 888.308.3620 or visit www.biomerix.com.

Medline Premier Contract For Surgical Mesh Biomaterials Expanded to Include REVIVE® and ASSURE® Soft Tissue Repair Mesh

Unique Biomerix Biomaterial Mimics the Nature and Function of >the Extracellular Matrix

Wednesday, April 13, 2011 — Medline Industries, Inc., the nation’s largest privately held manufacturer and distributor of healthcare supplies, announced today that REVIVE® and ASSURE® soft tissue repair mesh has been added to their national agreement with Premier Purchasing Partners for surgical mesh biomaterials.  The three-year agreement makes the products available to the more than 2,500 U.S. hospitals and 73,000 healthcare sites that are members of the Premier Healthcare Alliance.

REVIVE is constructed of the Biomerix Biomaterial™, a proprietary, biointegrative synthetic tissue scaffold.  This unique structure is designed to play a role similar to that of the body’s extracellular matrix, supporting organized tissue in growth.  The device is designed for repair and reinforcement in a variety of soft tissue procedures such as inguinal (or groin) hernias.

Inguinal hernias, which account for approximately 700,000 hernia operations annually in the U.S.¹ Statistically, the lifetime chance of having an inguinal hernia is 27 percent for men and 3 percent for women.² The surgical operation is intended to repair a protrusion of abdominal-cavity contents occurring through the inguinal canal.

ASSURE has two distinctly different sides, one with Biomerix Biomaterial and the opposite side a resorbable lactide caprolactone copolymer film designed to minimize tissue attachment to the device in case of direct contact with the viscera. It’s indicated for use in both open and laparoscopic ventral hernia repairs, soft tissue deficiencies and for the temporary bridging of fascial defects.

Ventral hernia repairs account for approximately 420,000 hernia repair operations annually in the U.S.³ When a ventral hernia occurs, it usually arises in the abdominal wall where the muscle has weakened or where a previous surgical incision was made.⁴

References:

¹ Rutkow I M. et al. Demographic, classificatory and socioeconomic aspects of hernia repair in the United States.  Surg Clin North Am. (1993); 73: 413–426. [PubMed]

² John T Jenkins, Patrick J O’Dwyer (2008). “Inguinal hernias”. BMJ 336: 269–272. doi:10.1136/bmj.39450.428275.AD.

³ U.S. Markets for Soft tissue repair 2008.  September 2007.  Millennium Research Group.

⁴ Patient Information for Laparoscopic Ventral Hernia Repair from SAGES. Mar. 2004. Society of American Gastrointestinal and Endoscopic Surgeons (SAGES). 7 June 2010 http://www.sages.org/publication/id/PI10/.

About Premier Healthcare Alliance

Malcolm Baldrige National Quality Award recipient Premier is a performance improvement alliance of more than 2,500 U.S. hospitals and 73,000-plus other healthcare sites using the power of collaboration to lead the transformation to high quality, cost-effective care. Owned suminat by hospitals, health systems and other providers, Premier maintains the nation’s most comprehensive repository of clinical, financial and outcomes information and operates a leading healthcare purchasing network. A world leader in helping deliver measurable improvements in care, Premier has worked with the Centers for Medicare & Medicaid Services and the United Kingdom’s National Health Service North West to improve hospital performance. Headquartered in Charlotte, N.C., Premier also has an office in Washington.

About Medline

Medline, recently named one of the “100 Best Places to Work in Healthcare,” manufactures and distributes more than 125,000 products to hospitals, extended care facilities, surgery centers, physician offices and home care dealers. Headquartered in Mundelein, Ill., Medline has more than 1,100 dedicated sales representatives nationwide to support its broad product line and cost management services.

Over the past five years, Medline has been the fastest-growing distributor of medical and surgical supplies in the U.S., serving as the primary distributor to over 450 major hospitals and healthcare systems. As a leading distributor, Medline offers a comprehensive array of consulting and management services encompassing the supply chain and logistics, utilization and standardization, business tools and enhanced reporting capabilities and on-staff clinicians.

Medline has a growing network of 50 manufacturing and distribution centers worldwide, as well as an expanding, dedicated transportation fleet with over 200 vehicles in a variety of sizes to fit customers’ specific delivery needs. The fleet is equipped with the latest navigation devices for enhanced order tracking and communication.

Biomerix Granted CE Mark for REVIVE™ Soft Tissue Repair Mesh

FREMONT, Calif., January 24, 2011 — Biomerix Corporation announced today that it has received CE Mark approval for its REVIVE™ soft tissue repair mesh allowing for the marketing of REVIVE in all European Union member (EU) states. REVIVE received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in January 2009.

REVIVE is constructed of the Biomerix Biomaterial™, a proprietary, biointegrative synthetic tissue scaffold. This unique structure is designed to play a role similar to that of the body’s extracellular> matrix, supporting organized tissue ingrowth. The device is designed for repair and reinforcement in a variety of soft tissue procedures such as inguinal hernias.

Over 700,000 inguinal hernia repair procedures are performed annually in Europe. Inguinal hernias occur when soft tissue, usually part of the intestines, protrudes through a weak point or tear in the lower abdominal wall. Synthetic mesh is commonly used to reinforce the repair and support the surrounding tissue. REVIVE is designed to facilitate robust tissue ingrowth, while minimizing the scarring response typically associated with implantation of a mesh. Mesh contraction and intense scarring can lead to persistent groin pain. Initial feedback from users of REVIVE has confirmed excellent ease of use and conformability to the anatomy. The soft, pliable nature of the mesh easily adapts to the anatomy allowing for easy delivery, positioning and fixation of the mesh.

“This latest approval represents another important milestone in Biomerix’s plans to develop innovative products based on its proprietary materials and capabilities,” said Kenneth G. Hayes, President and CEO of Biomerix Corporation. “REVIVE will be distributed in the EU by Medline Industries pursuant to our exclusive distribution agreement.”

About Biomerix

Biomerix Corporation develops and manufactures novel and proprietary materials to meet the needs of the medical, industrial, and consumer markets. Founded in 2001, Biomerix began developing a new class of polymeric material designed to support the tissue healing process. By 2004, the Company achieved a significant breakthrough and created the proprietary Biomerix Biomaterial™, a revolutionary biointegrative synthetic tissue scaffold. The Biomerix Biomaterial is a non-resorbable, cross linked, reticulated, polycarbonate polyurethane-urea consisting of an open-cell, three-dimensional, interconnected macroporous structure. This unique scaffold translates into an ability to support predictable, organized fibrovascular tissue ingrowth. The Biomerix Biomaterial is designed to play a role similar to the body’s extracellular matrix (ECM), through the main phases of inflammation, proliferation, and remodeling.

Biomerix Corporation Signs Distribution Agreement with Medline Industries, Inc.

FREMONT, Calif., October 25 /PRNewswire/ – Biomerix Corporation, a medical technology company developing and manufacturing innovative hernia repair products, today announced that it has entered into an exclusive distribution agreement with Medline Industries, Inc., the nation’s largest privately held manufacturer and distributor of medical and surgical products in the United States. Pursuant to the terms of the agreement, Medline will commercialize Biomerix’s novel composite soft tissue repair devices ASSURE™ and REVIVE™ in North America and Europe.

ASSURE™ with two distinctly different sides, features the Biomerix Biomaterial™ on one side, developed to facilitate rapid tissue ingrowth and healthy biointegration, and on the opposite side, the resorbable lactide caprolactone copolymer film designed to minimize tissue attachment to the device in case of direct contact with the viscera. ASSURE™ is indicated for use in both open and laparoscopic ventral hernia repairs, soft tissue deficiencies, and for the temporary bridging of fascial defects.

REVIVE™ also featuring the Biomerix Biomaterial™, acts as an ideal three-dimensional tissue scaffold facilitating rapid tissue ingrowth and the body’s natural healing process. The unique construction of REVIVE™ is engineered to optimize handling characteristics and deliver high mechanical strength. The novel device can be utilized in a variety of soft tissue repair procedures and for both open and laparoscopic inguinal hernia repairs.

Kenneth G. Hayes, President and Chief Executive Officer of Biomerix Corporation stated, “We are pleased with this agreement and look forward to a successful, valuable partnership with Medline. A skilled distribution and sales organization, Medline offers a broad field presence and a robust infrastructure. We believe both ASSURE™ and REVIVE™ incorporating the novel Biomerix Biomaterial™, represent a significant technological advance in the repair of hernias and soft tissue deficiencies.”

Medline recently announced the signing of a three-year national agreement with Premier Purchasing Partners, the group purchasing unit of Premier, Inc., to provide surgical mesh biomaterials used in soft tissue reinforcement to the more than 2,200 U.S. hospitals and 58,000 healthcare sites that are members of the Premier healthcare alliance. The agreement, which took effect October 1, 2010, includes ASSURE™ and REVIVE™ products for the repair and reinforcement of hernia and other fascial defects.

“The addition of ASSURE™ and REVIVE™ with the unique Biomerix Biomaterial™, is a logical next step in our strategic effort to provide a broad portfolio of high quality products in the field of hernia repair”, said Medline’s Divisional Vice President, Marc Lessem. “As we expand into more unique and sophisticated product lines, Biomerix offers the perfect blend of value and technology.”

About Biomerix

Biomerix Corporation develops and manufactures novel and proprietary materials to meet the needs of the medical, industrial, and consumer markets. Founded in 2001, Biomerix began developing a new class of polymeric material designed to support the tissue healing process. By 2004, the Company achieved a significant breakthrough and created the proprietary Biomerix Biomaterial™, a revolutionary biointegrative synthetic tissue scaffold.
The Biomerix Biomaterial™ is a non-resorbable, cross linked, reticulated, polycarbonate polyurethane-urea consisting of an open-cell, three-dimensional, interconnected macroporous structure. This unique scaffold translates into an ability to support predictable, organized fibrovascular tissue ingrowth. The Biomerix Biomaterial™ is designed to play a role similar to the body’s extracellular matrix (ECM), through the main phases of inflammation, proliferation, and remodeling.

To maximize the value of its material platform technology and capabilities, Biomerix has implemented a multifaceted business model. The Company selectively develops and manufactures OEM finished medical devices using the Biomerix Biomaterial™, supplies the Biomerix Biomaterial™ as a component for other medical devices; and collaboratively designs and develops custom materials with select business partners. For more information please call 888.308.3620 or visit www.biomerix.com.

About Medline

Medline, the nation’s largest privately held manufacturer and distributor of healthcare products, manufactures and distributes more than 100,000 products to hospitals, extended care facilities, surgery centers, home care dealers and agencies. Headquartered in Mundelein, IL, Medline has more than 900 dedicated sales representatives nationwide to support its broad product line and cost management services.

Over the past five years, Medline has been the fastest growing distributor of medical and surgical supplies in the U.S., serving as the primary distributor to over 450 major hospitals and health care systems. As a leading distributor, Medline offers a comprehensive array of consulting and management services encompassing the supply chain and logistics, utilization and standardization, business tools and enhanced reporting capabilities, and on-staff clinicians.

Biomerix Granted US Patent for Its Proprietary Biomaterial Platform Technology

Fremont, CA – October 13, 2010 – Biomerix Corporation today announced that the United States Patent and Trademark Office (USPTO) has granted a patent for its proprietary biomaterial platform technology titled “Reticulated elastomeric matrices, their manufacture and use in implantable devices.” The Company’s platform technology, the Biomerix Biomaterial™ is a non-resorbable reticulated, polycarbonate polyurethane-urea, consisting of an open-cell, three-dimensional, interconnected tissue scaffold. The novel structure of the biomaterial translates into an ability to support predictable, organized fibrovascular tissue ingrowth and remodeling.

The Biomerix Biomaterial is designed to play a role similar to the body’s extracellular matrix (ECM), through the main phases of inflammation, proliferation, and remodeling. Benefits of the Biomerix Biomaterial extend beyond medical device applications. The material’s unique structure and chemistry impart differentiated benefits including high porosity, excellent resilience, long-term durability and superior chemical compatibility over current polymeric materials. It is these advantages that make the Biomerix Biomaterial a compelling alternative for potential industrial and consumer applications.

“Biomerix secured one of its most important intellectual property assets representing a significant milestone for our company and is the culmination of extensive research and development,” stated Kenneth G. Hayes, President and Chief Executive Officer of Biomerix Corporation. “The scope of this technology is far reaching and has the potential to drive technological innovation across a broad spectrum of applications in the medical, industrial, and consumer industries.”

The US patent number is 7,803,395.

About Biomerix Corporation

Biomerix Corporation develops and manufactures novel and proprietary materials to meet the needs of medical, industrial, and consumer markets. The Company has successfully developed its first biomaterial platform, the Biomerix Biomaterial™, which is a non-resorbable, polycarbonate polyurethane-urea scaffold that has been shown to support fibrovascular tissue in-growth in a wide range of preclinical studies. The Biomerix Biomaterial has received U.S. FDA clearance for vascular, orthopedic, and soft tissue repair applications.

For more information please call 888.308.3620 or visit www.biomerix.com

Biomerix Corporation and Synthecon Announce Strategic Distribution Agreement

FREMONT, Calif., Sept. 20 /PRNewswire/ — Biomerix Corporation, a medical technologies company developing and manufacturing innovative regenerative medicine biomaterials, and Synthecon, a leading biotechnology company specializing in the design and manufacturing of rotating cell culture systems, today announced a strategic distribution agreement for three-dimensional cell culture scaffolds developed using Biomerix Corporation’s unique biomaterial technology.

The Biomerix 3D Scaffold is a medical grade biomaterial that embodies a novel microarchitecture, consisting of an interconnected three dimensional network of cells and pores designed to support tissue ingrowth and biointegration. Used in concert with Synthecon’s bioreactors, the 3D Scaffold serves as an ideal technology to create an environment conducive to the growth of cells and tissues. Under the agreement, Biomerix will develop and manufacture the Biomerix 3D Scaffold, which Synthecon will market and sell nationwide for research applications. Specific terms of the agreement were not disclosed.

“Synthecon investigators have had excellent results using this material in its Rotary bioreactors to create 3-D cell cultures. Synthecon is currently utilizing the Biomerix 3-D Scaffold in an NIH-funded project to scale-up production of hematopoietic stem cells. The fact that Biomerix 3-D Scaffold is already approved for human use and is very compatible with the Rotary Cell Culture System gives us a high degree of confidence that the combination of these two technologies will lead to many exciting applications in the field of tissue engineering,” commented Bill Anderson, CEO of Synthecon.

“Partnering with Synthecon allows us to be on the forefront of regenerative medicine and represents a significant growth opportunity for our Company,” said Kenneth Hayes, President and Chief Executive Officer of Biomerix Corporation. “Synthecon is well respected as a leader in 3D cell culture systems and we look forward to a productive partnership,” he concluded.

About Biomerix Corporation

Biomerix Corporation develops and manufactures novel materials for the medical, industrial, and consumer markets. The Company has successfully developed its first biomaterial platform, the Biomerix Biomaterial™, which is a non-resorbable, polycarbonate polyurethane-urea scaffold that has been shown to support fibrovascular tissue in-growth in a wide range of preclinical studies. The Biomerix Biomaterial has received U.S. FDA clearance for vascular, orthopedic, and soft tissue repair applications.

For more information please call 888.308.3620 or visit www.biomerix.com

About Synthecon Inc.

Synthecon designs and manufactures rotating bioreactors used in cell culture and tissue engineering applications. In addition to being recognized as a “Fast Tech Fifty” company, Synthecon was a previous recipient of the “R&D 100″ award for its technology. Originally based on a license from NASA for the rotating wall bioreactor, Synthecon has gone on to design and patent numerous innovations to the basic technology. Marketed under the trademark Rotary Cell Culture System™, Synthecon bioreactors are recognized in several  hundred peer-reviewed scientific publications to be a leader in growing three-dimensional  human tissue analogs.

For more information please call 800-853-0740 or visit www.synthecon.com